About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Early Relapse: Choosing Among Different Second Line Regimens in Myeloma
By
Ajay Nooka
16 Videos
October 13, 2017
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights 2023: State of the Art and Next Questions
Wed, Nov 1, 2023
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
18:26
William Schaffner
Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
12:33
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…
Feat.
K. Patel
07:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…
Feat.
L. Shune
44:49
Dana-Farber Cancer Institute
Recent Updates in Multiple Myeloma
Feat.
K. Anderson
05:22
PrecisCa
Teclistamab in R/R Multiple Myeloma: Results From the MajesTEC-1 Tri…
Feat.
A. Nooka
52:39
Yale Cancer Center
Myeloma in 2023: So Many Drugs, Yet So Few Cures
Feat.
A. Chari
15:08
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
New Therapies for Relapsed Myeloma in 2023
Feat.
D. Vogl
06:11
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…
Feat.
A. Varshavsky-Yanovsky
30:59
Houston Methodist Hospital
Overview of Advances in Multiple Myeloma
Feat.
S. Ganguly
15:54
Paul Richardson
Emerging Strategies in the Management of Relapsed MM
11:20
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "First Phase 3 Results From CARTITUDE-4 - …
Feat.
B. Dhakal
32:03
Indy Hematology Review
Emerging and Current Treatment of MM: What Should We Know and What S…
Feat.
K. Anderson
20:50
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
The Multiple Roadblocks to Access for CAR-T in MM: Optimizing Road C…
Feat.
K. Patel
20:11
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Combination Therapy Trials in Myeloma - A …
Feat.
A. Jakubowiak
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
04:17
ecancer
ASCO® 2023 Insights: "CARTITUDE-4 Study Summary - Cilta-Cel Vs.…
Feat.
B. Dhakal
